Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?

Mateo Aboy; Cristina Crespo; Kathleen Liddell; Johnathon Liddicoat; Matthew Jordan

doi:10.1038/nbt.4308

Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?

Mateo Aboy, Cristina Crespo, Kathleen Liddell, Johnathon Liddicoat, Matthew Jordan

Laws

University of Cambridge

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Original language	English
Pages (from-to)	1146-1149
Number of pages	4
Journal	Nature Biotechnology
Volume	36
Issue number	12
DOIs	https://doi.org/10.1038/nbt.4308
Publication status	Published - 6 Dec 2018

Keywords

Biological Products
Biotechnology/legislation & jurisprudence
DNA/genetics
Patents as Topic
United States

Access to Document

10.1038/nbt.4308

Cite this

@article{bba05d7df8ff40acb767c85c91ae3c30,

title = "Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?",

keywords = "Biological Products, Biotechnology/legislation & jurisprudence, DNA/genetics, Patents as Topic, United States",

author = "Mateo Aboy and Cristina Crespo and Kathleen Liddell and Johnathon Liddicoat and Matthew Jordan",

year = "2018",

month = dec,

day = "6",

doi = "10.1038/nbt.4308",

language = "English",

volume = "36",

pages = "1146--1149",

journal = "Nature Biotechnology",

issn = "1087-0156",